<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>peripheral edema &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/peripheral-edema/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 12:54:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>peripheral edema &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Gastric Cancer Drug Zolbetuximab Drives Widespread Albumin Loss in Real-World Patients</title>
		<link>https://bioengineer.org/gastric-cancer-drug-zolbetuximab-drives-widespread-albumin-loss-in-real-world-patients/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 12:54:06 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[advanced gastric cancer]]></category>
		<category><![CDATA[albumin recovery]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[CLDN18.2]]></category>
		<category><![CDATA[gastric cancer]]></category>
		<category><![CDATA[hypoalbuminemia]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[peripheral edema]]></category>
		<category><![CDATA[protein-losing enteropathy]]></category>
		<category><![CDATA[Real-world study]]></category>
		<category><![CDATA[treatment interruption]]></category>
		<category><![CDATA[zolbetuximab]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=427275</guid>

					<description><![CDATA[A real-world study finds that every patient treated with zolbetuximab for CLDN18.2-positive advanced gastric cancer developed hypoalbuminemia, with prior total gastrectomy and persistent nausea identifying risk and temporary treatment interruption linked to albumin recovery.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">427275</post-id>	</item>
	</channel>
</rss>
